BioXcel Therapeutics selects Teva as stalking horse for $57.5M sale
BioXcel Therapeutics has picked Teva as the stalking horse for a $57.5M asset sale, with up to $87.5M in milestones.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.